Enzon Pharmaceuticals, Inc. (ENZN)
USD 0.08
(-18.9%)
USD 0.08
(-18.9%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -47.01 Million USD | -0.06% |
| 2022 | -46.98 Million USD | 1.38% |
| 2021 | -47.64 Million USD | 1.04% |
| 2020 | -48.14 Million USD | -783.99% |
| 2019 | -5.44 Million USD | 16.22% |
| 2018 | -6.5 Million USD | 13.08% |
| 2017 | -7.47 Million USD | 2.11% |
| 2016 | -7.63 Million USD | 34.55% |
| 2015 | -11.67 Million USD | 66.23% |
| 2014 | -34.56 Million USD | -430.09% |
| 2013 | -6.52 Million USD | -116.93% |
| 2012 | 38.5 Million USD | 52.93% |
| 2011 | 25.17 Million USD | 109.57% |
| 2010 | -263.03 Million USD | -231.77% |
| 2009 | 199.61 Million USD | 4.62% |
| 2008 | 190.78 Million USD | -37.92% |
| 2007 | 307.33 Million USD | -16.76% |
| 2006 | 369.21 Million USD | 60.89% |
| 2005 | 229.48 Million USD | -25.61% |
| 2004 | 308.46 Million USD | -7.44% |
| 2003 | 333.24 Million USD | 16.46% |
| 2002 | 286.14 Million USD | 218.73% |
| 2001 | 89.77 Million USD | 381.12% |
| 2000 | -31.93 Million USD | -29.29% |
| 1999 | -24.7 Million USD | -280.0% |
| 1998 | -6.5 Million USD | 21.69% |
| 1997 | -8.3 Million USD | 34.65% |
| 1996 | -12.7 Million USD | -56.79% |
| 1995 | -8.1 Million USD | -42.11% |
| 1994 | -5.7 Million USD | 52.5% |
| 1993 | -12 Million USD | -8.11% |
| 1992 | -11.1 Million USD | 53.16% |
| 1991 | -23.7 Million USD | -15.61% |
| 1990 | -20.5 Million USD | -230.65% |
| 1989 | -6.2 Million USD | 6.06% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -45.98 Million USD | 2.18% |
| 2024 Q3 | -46.63 Million USD | -0.87% |
| 2024 Q2 | -46.22 Million USD | -0.52% |
| 2023 Q3 | -46.55 Million USD | -0.92% |
| 2023 Q2 | -46.13 Million USD | -0.55% |
| 2023 FY | -47.01 Million USD | -0.06% |
| 2023 Q1 | -45.87 Million USD | 2.35% |
| 2023 Q4 | -47.01 Million USD | -0.98% |
| 2022 Q3 | -46.85 Million USD | -0.12% |
| 2022 Q2 | -46.79 Million USD | 1.34% |
| 2022 Q4 | -46.98 Million USD | -0.28% |
| 2022 Q1 | -47.42 Million USD | 0.44% |
| 2022 FY | -46.98 Million USD | 1.38% |
| 2021 Q4 | -47.64 Million USD | 0.52% |
| 2021 Q1 | -48.18 Million USD | -0.09% |
| 2021 FY | -47.64 Million USD | 1.04% |
| 2021 Q2 | -48.19 Million USD | -0.01% |
| 2021 Q3 | -47.89 Million USD | 0.62% |
| 2020 Q4 | -48.14 Million USD | -806.46% |
| 2020 FY | -48.14 Million USD | -783.99% |
| 2020 Q1 | -5.14 Million USD | 5.55% |
| 2020 Q2 | -5.9 Million USD | -14.87% |
| 2020 Q3 | -5.31 Million USD | 10.12% |
| 2019 FY | -5.44 Million USD | 16.22% |
| 2019 Q2 | -3.36 Million USD | 5.37% |
| 2019 Q1 | -3.55 Million USD | 45.26% |
| 2019 Q3 | -10.01 Million USD | -197.48% |
| 2019 Q4 | -5.44 Million USD | 45.63% |
| 2018 Q4 | -6.5 Million USD | 3.36% |
| 2018 Q1 | -7.24 Million USD | 3.18% |
| 2018 Q2 | -6.96 Million USD | 3.78% |
| 2018 Q3 | -6.72 Million USD | 3.45% |
| 2018 FY | -6.5 Million USD | 13.08% |
| 2017 FY | -7.47 Million USD | 2.11% |
| 2017 Q4 | -7.47 Million USD | -73.1% |
| 2017 Q3 | -4.32 Million USD | 61.45% |
| 2017 Q2 | -11.2 Million USD | -38.71% |
| 2017 Q1 | -8.07 Million USD | -5.76% |
| 2016 Q2 | -11.23 Million USD | -15.37% |
| 2016 Q1 | -9.73 Million USD | 16.6% |
| 2016 Q3 | -12.89 Million USD | -14.83% |
| 2016 FY | -7.63 Million USD | 34.55% |
| 2016 Q4 | -7.63 Million USD | 40.76% |
| 2015 Q2 | -38.99 Million USD | -12.04% |
| 2015 Q3 | -20.25 Million USD | 48.05% |
| 2015 Q4 | -11.67 Million USD | 42.37% |
| 2015 FY | -11.67 Million USD | 66.23% |
| 2015 Q1 | -34.8 Million USD | -0.7% |
| 2014 FY | -34.56 Million USD | -430.09% |
| 2014 Q3 | -28.99 Million USD | -35.0% |
| 2014 Q2 | -21.47 Million USD | -44.5% |
| 2014 Q1 | -14.86 Million USD | -127.96% |
| 2014 Q4 | -34.56 Million USD | -19.21% |
| 2013 Q2 | -11.45 Million USD | -94.4% |
| 2013 FY | -6.52 Million USD | -116.93% |
| 2013 Q3 | -21.69 Million USD | -89.34% |
| 2013 Q4 | -6.52 Million USD | 69.94% |
| 2013 Q1 | -5.89 Million USD | -115.31% |
| 2012 Q2 | 56.4 Million USD | -29.08% |
| 2012 FY | 38.5 Million USD | 52.93% |
| 2012 Q4 | 38.5 Million USD | 253.41% |
| 2012 Q3 | -25.09 Million USD | -144.49% |
| 2012 Q1 | 79.53 Million USD | 215.93% |
| 2011 Q1 | -235.43 Million USD | 10.49% |
| 2011 FY | 25.17 Million USD | 109.57% |
| 2011 Q2 | -183.36 Million USD | 22.12% |
| 2011 Q4 | 25.17 Million USD | 114.77% |
| 2011 Q3 | -170.49 Million USD | 7.02% |
| 2010 Q2 | -264.68 Million USD | -14.73% |
| 2010 Q4 | -263.03 Million USD | 4.04% |
| 2010 FY | -263.03 Million USD | -231.77% |
| 2010 Q1 | -230.7 Million USD | -215.58% |
| 2010 Q3 | -274.09 Million USD | -3.56% |
| 2009 FY | 199.61 Million USD | 4.62% |
| 2009 Q4 | 199.61 Million USD | -0.91% |
| 2009 Q3 | 201.43 Million USD | -0.87% |
| 2009 Q2 | 203.2 Million USD | 15.46% |
| 2009 Q1 | 175.99 Million USD | -7.75% |
| 2008 Q2 | 222.09 Million USD | -1.22% |
| 2008 FY | 190.78 Million USD | -37.92% |
| 2008 Q4 | 190.78 Million USD | -3.09% |
| 2008 Q3 | 196.87 Million USD | -11.36% |
| 2008 Q1 | 224.82 Million USD | -26.85% |
| 2007 Q4 | 307.33 Million USD | -8.41% |
| 2007 Q3 | 335.56 Million USD | -6.14% |
| 2007 FY | 307.33 Million USD | -16.76% |
| 2007 Q1 | 371.28 Million USD | 0.56% |
| 2007 Q2 | 357.49 Million USD | -3.71% |
| 2006 FY | 369.21 Million USD | 60.89% |
| 2006 Q2 | 364.11 Million USD | -1.34% |
| 2006 Q1 | 369.05 Million USD | 0.0% |
| 2006 Q4 | 369.21 Million USD | -2.4% |
| 2006 Q3 | 378.27 Million USD | 3.89% |
| 2005 Q3 | 372.41 Million USD | 8.43% |
| 2005 FY | 229.48 Million USD | -25.61% |
| 2005 Q2 | 343.44 Million USD | -4.29% |
| 2005 Q1 | 358.84 Million USD | 8.57% |
| 2004 Q2 | 308.46 Million USD | -2.58% |
| 2004 Q3 | 323.94 Million USD | 5.02% |
| 2004 FY | 308.46 Million USD | -7.44% |
| 2004 Q4 | 330.52 Million USD | 2.03% |
| 2004 Q1 | 316.63 Million USD | 1.86% |
| 2003 FY | 333.24 Million USD | 16.46% |
| 2003 Q1 | 328.19 Million USD | 9.16% |
| 2003 Q2 | 333.24 Million USD | 1.54% |
| 2003 Q3 | 336.95 Million USD | 1.11% |
| 2003 Q4 | 310.83 Million USD | -7.75% |
| 2002 FY | 286.14 Million USD | 218.73% |
| 2002 Q1 | 271.37 Million USD | 26.06% |
| 2002 Q3 | 244.28 Million USD | -14.63% |
| 2002 Q2 | 286.14 Million USD | 5.44% |
| 2002 Q4 | 300.64 Million USD | 23.07% |
| 2001 Q2 | 89.77 Million USD | 448.01% |
| 2001 FY | 89.77 Million USD | 381.12% |
| 2001 Q4 | 215.27 Million USD | 480.74% |
| 2001 Q3 | 37.06 Million USD | -58.71% |
| 2001 Q1 | -25.79 Million USD | 6.45% |
| 2000 Q2 | -31.93 Million USD | 74.77% |
| 2000 FY | -31.93 Million USD | -29.29% |
| 2000 Q4 | -27.57 Million USD | -1.18% |
| 2000 Q3 | -27.25 Million USD | 14.65% |
| 2000 Q1 | -126.55 Million USD | -443.16% |
| 1999 Q4 | -23.3 Million USD | 5.28% |
| 1999 Q1 | -24.8 Million USD | -4.64% |
| 1999 Q2 | -24.7 Million USD | 0.4% |
| 1999 FY | -24.7 Million USD | -280.0% |
| 1999 Q3 | -24.6 Million USD | 0.4% |
| 1998 FY | -6.5 Million USD | 21.69% |
| 1998 Q3 | -23 Million USD | -253.85% |
| 1998 Q1 | -6.6 Million USD | 24.14% |
| 1998 Q2 | -6.5 Million USD | 1.52% |
| 1998 Q4 | -23.7 Million USD | -3.04% |
| 1997 Q3 | -9.6 Million USD | -15.66% |
| 1997 Q4 | -8.7 Million USD | 9.38% |
| 1997 Q1 | -9.6 Million USD | 7.69% |
| 1997 FY | -8.3 Million USD | 34.65% |
| 1997 Q2 | -8.3 Million USD | 13.54% |
| 1996 Q4 | -10.4 Million USD | 14.75% |
| 1996 FY | -12.7 Million USD | -56.79% |
| 1996 Q1 | -12.8 Million USD | -141.51% |
| 1996 Q2 | -12.7 Million USD | 0.78% |
| 1996 Q3 | -12.2 Million USD | 3.94% |
| 1995 Q2 | -8.1 Million USD | -72.34% |
| 1995 Q4 | -5.3 Million USD | 19.7% |
| 1995 Q3 | -6.6 Million USD | 18.52% |
| 1995 Q1 | -4.7 Million USD | -38.24% |
| 1995 FY | -8.1 Million USD | -42.11% |
| 1994 Q2 | -5.7 Million USD | 0.0% |
| 1994 Q3 | -4.7 Million USD | 17.54% |
| 1994 FY | -5.7 Million USD | 52.5% |
| 1994 Q4 | -3.4 Million USD | 27.66% |
| 1994 Q1 | -5.7 Million USD | -7.55% |
| 1993 Q1 | -20.5 Million USD | -162.82% |
| 1993 Q4 | -5.3 Million USD | -6.0% |
| 1993 FY | -12 Million USD | -8.11% |
| 1993 Q3 | -5 Million USD | 58.33% |
| 1993 Q2 | -12 Million USD | 41.46% |
| 1992 Q3 | -9.2 Million USD | 17.12% |
| 1992 FY | -11.1 Million USD | 53.16% |
| 1992 Q4 | -7.8 Million USD | 15.22% |
| 1992 Q2 | -11.1 Million USD | 28.85% |
| 1992 Q1 | -15.6 Million USD | -2.63% |
| 1991 FY | -23.7 Million USD | -15.61% |
| 1991 Q4 | -15.2 Million USD | 21.24% |
| 1991 Q1 | -12.1 Million USD | 22.44% |
| 1991 Q3 | -19.3 Million USD | 18.57% |
| 1991 Q2 | -23.7 Million USD | -95.87% |
| 1990 Q4 | -15.6 Million USD | 8.77% |
| 1990 Q2 | -20.5 Million USD | 0.0% |
| 1990 Q3 | -17.1 Million USD | 16.59% |
| 1990 FY | -20.5 Million USD | -230.65% |
| 1989 Q2 | -6.2 Million USD | 0.0% |
| 1989 FY | -6.2 Million USD | 6.06% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 42.79 Million USD | 209.859% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 7653.779% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -18733.427% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -230260.643% |
| Qrons Inc. | 351.42 Thousand USD | 13477.458% |
| Rebus Holdings, Inc. | 305 Thousand USD | 15513.77% |
| Skye Bioscience, Inc. | -5.72 Million USD | -721.689% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -645.687% |
| Adynxx, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -3588602.29% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 208.238% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 236733.614% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 932.311% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 398.243% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 1241.615% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 11798.922% |
| SQZ Biotechnologies Company | -36.23 Million USD | -29.731% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 2196.66% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 5170.396% |
| Mesoblast Limited | 55.85 Million USD | 184.163% |
| Marizyme, Inc. | 18.56 Million USD | 353.174% |
| Genus plc | 190.6 Million USD | 124.665% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 2202.662% |
| Pharming Group N.V. | 109.8 Million USD | 142.814% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 5564.98% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 3972.845% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 7013.529% |
| ContraFect Corporation | -6.02 Million USD | -680.153% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 35017.075% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 4168.792% |
| IMV Inc. | 7.67 Million USD | 712.892% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 954.469% |
| MultiCell Technologies, Inc. | 90.04 USD | 52212450.067% |
| ONE Bio Corp. | 9.04 Million USD | 620.042% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -6305.097% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 463.139% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 3536.623% |
| Q BioMed Inc. | 4.06 Million USD | 1257.929% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 253.865% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 4765.203% |
| Biomind Labs Inc. | 711.4 Thousand USD | 6708.359% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 177.647% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 2451.315% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 467.092% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 13169.417% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 33727.078% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 2234.987% |
| GB Sciences, Inc. | 1.74 Million USD | 2790.526% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -25479.472% |
| HST Global, Inc. | 96.79 Thousand USD | 48669.628% |
| CSL Limited | 10.52 Billion USD | 100.447% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 22897.345% |
| Halberd Corporation | 144.72 Thousand USD | 32584.574% |
| Enzolytics Inc. | 981.65 Thousand USD | 4889.05% |
| Agentix Corp. | 37.63 Thousand USD | 125028.915% |
| Resverlogix Corp. | 6.45 Million USD | 828.755% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -6884.515% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 97.683% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 764.859% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 1835.647% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -431.815% |
| AVAX Technologies, Inc. | -5.9 Million USD | -696.381% |
| Zenith Capital Corp. | 10.06 Thousand USD | 467230.366% |
| Genscript Biotech Corporation | -1.06 Billion USD | 95.57% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 23555.336% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 2070.299% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 28677.16% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -256543.738% |
| Kadimastem Ltd | -253.1 Thousand USD | -18474.33% |
| Helix BioMedix, Inc. | -2.57 Million USD | -1729.238% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 331.86% |
| BioStem Technologies, Inc. | 4.47 Million USD | 1151.25% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 23459.536% |
| LadRx Corporation | -2.03 Million USD | -2208.506% |
| Cell Source, Inc. | 9.23 Million USD | 609.23% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 7501.518% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 7501.518% |
| NovAccess Global Inc. | 2.17 Million USD | 2258.033% |
| Affymax, Inc. | -5.59 Million USD | -739.95% |
| Itoco Inc. | 228.3 Thousand USD | 20691.752% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 34670.443% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 1048.396% |
| Mobile Lads Corp. | 484.23 Thousand USD | 9808.569% |
| CytoDyn Inc. | 20.26 Million USD | 332.021% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -7266051.468% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -507132.147% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 710.07% |
| SYBLEU INC | 473.71 Thousand USD | 10024.131% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 1154.785% |
| International Stem Cell Corporation | 2.59 Million USD | 1915.135% |
| Bioxytran, Inc. | 1.89 Million USD | 2575.731% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 75424.051% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 2255.624% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 1469.016% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 649.655% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 6184.853% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -3660.96% |
| Neutra Corp. | 52.18 Thousand USD | 90183.737% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -1788.791% |
| PureTech Health plc | -167.19 Million USD | 71.882% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -19095.78% |
| IXICO plc | -4.44 Million USD | -957.736% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 455.64% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 185.709% |
| CSL Limited | 10.52 Billion USD | 100.447% |
| Cellectis S.A. | -43.81 Million USD | -7.287% |